D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright cut their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley lowered their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.89.

Invivyd Stock Down 13.1 %

NASDAQ:IVVD opened at $0.46 on Friday. Invivyd has a 52 week low of $0.40 and a 52 week high of $5.20. The company has a fifty day simple moving average of $0.65 and a two-hundred day simple moving average of $0.91. The company has a market cap of $55.20 million, a price-to-earnings ratio of -0.24 and a beta of 0.64.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the sale, the director now owns 4,202,679 shares in the company, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 816,466 shares of company stock valued at $423,214. Insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Several institutional investors have recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the 3rd quarter worth $27,000. XTX Topco Ltd lifted its position in Invivyd by 68.1% in the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares during the period. Cornercap Investment Counsel Inc. purchased a new stake in Invivyd in the 2nd quarter valued at approximately $86,000. Rhumbline Advisers increased its position in Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Invivyd during the 2nd quarter worth approximately $115,000. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.